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Abstract
Background: Impaired glucose tolerance (IGT) is a prediabetic state. If IGT can be prevented
from progressing to overt diabetes, hyperglycemia-related complications can be avoided. The
purpose of the present study was to examine whether pioglitazone (ACTOS®) can prevent
progression of IGT to type 2 diabetes mellitus (T2DM) in a prospective randomized, double blind,
placebo controlled trial.
Methods/Design: 602 IGT subjects were identified with OGTT (2-hour plasma glucose = 140–
199 mg/dl). In addition, IGT subjects were required to have FPG = 95–125 mg/dl and at least one
other high risk characteristic. Prior to randomization all subjects had measurement of ankle-arm
blood pressure, systolic/diastolic blood pressure, HbA1C, lipid profile and a subset had frequently
sampled intravenous glucose tolerance test (FSIVGTT), DEXA, and ultrasound determination of
carotid intima-media thickness (IMT). Following this, subjects were randomized to receive
pioglitazone (45 mg/day) or placebo, and returned every 2–3 months for FPG determination and
annually for OGTT. Repeat carotid IMT measurement was performed at 18 months and study end.
Recruitment took place over 24 months, and subjects were followed for an additional 24 months.
At study end (48 months) or at time of diagnosis of diabetes the OGTT, FSIVGTT, DEXA, carotid
IMT, and all other measurements were repeated.
Primary endpoint is conversion of IGT to T2DM based upon FPG  126 or 2-hour PG  200 mg/
dl. Secondary endpoints include whether pioglitazone can: (i) improve glycemic control (ii) enhance
insulin sensitivity, (iii) augment beta cell function, (iv) improve risk factors for cardiovascular
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disease, (v) cause regression/slow progression of carotid IMT, (vi) revert newly diagnosed diabetes
to normal glucose tolerance.
Conclusion: ACT NOW is designed to determine if pioglitazone can prevent/delay progression
to diabetes in high risk IGT subjects, and to define the mechanisms (improved insulin sensitivity
and/or enhanced beta cell function) via which pioglitazone exerts its beneficial effect on glucose
metabolism to prevent/delay onset of T2DM.
Trial Registration: clinical trials.gov identifier: NCT00220961
Background
Type 2 diabetes mellitus (T2DM) affects 21 million Amer-
icans [1] and approximately 194 million individuals
world wide [2] and its prevalence is rapidly increasing [3].
Microvascular [4] and macrovascular [5] complications
are common in T2DM and both are strongly related to the
severity and duration of hyperglycemia [6-8]. The esti-
mated cost for the treatment of T2DM and related compli-
cations in year 2007 was 174 billion dollars [9].
The natural history of T2DM has been well defined [10-
14], starting with a genetic predisposition and progression
from normal glucose tolerance with insulin resistance to
impaired glucose tolerance with superimposition of beta
cell failure on insulin resistance, and eventually to overt
T2DM characterized by severe beta cell failure and insulin
resistance.
Because of the central role that hyperglycemia plays in the
development of both micro- and macrovascular compli-
cations [4-8], it follows that interventions designed to pre-
vent or delay the onset of hyperglycemia would be
effective in preventing these long term complications.
Recent studies have demonstrated that life style modifica-
tion [15,16] and therapy with metformin [16] and thiazo-
lidinediones [14,17,18] can prevent or delay the onset of
T2DM in high risk subjects. Individuals with impaired
glucose tolerance (IGT) represent a high risk group, with
a conversion rate that varies from 3–13% per year,
depending upon the ethnic group [19].
Individuals with IGT are characterized by defects in both
insulin secretion and insulin sensitivity [20-22]. There-
fore, interventions designed to enhance beta cell function
and ameliorate insulin resistance would be expected to be
effective in preventing the progression of IGT to T2DM.
Pioglitazone and other thiazolidinediones have been
shown both to enhance muscle/hepatic/adipocyte insulin
sensitivity [23-26] and to improve beta cell function
[16,18,27,28]. Because thiazolidinediones reverse the
characteristic defects present in IGT and T2DM, they rep-
resent a logical choice to prevent/delay the onset of diabe-
tes in high risk individuals.
Methods/Design
Primary Objective
The primary purpose is to examine whether treatment of
individuals with IGT with pioglitazone can prevent or
delay the development of T2DM.
Secondary Objectives
Secondary objectives include whether pioglitazone can:
(i) improve glycemic control; (ii) enhance insulin sensi-
tivity; (iii) improve beta cell function; (iv) improve risk
factors for cardiovascular disease; (v) cause regression/
slow progression of carotid intima-media thickness, (vi)
decrease microalbuminura; (vii) revert newly diagnosed
type 2 diabetic subjects to a state of normal glucose toler-
ance.
Overall Study Design/Subject Eligibility
The study is a prospective, randomized, double-blind pla-
cebo controlled trial to examine the efficacy of pioglita-
zone in reducing the incidence of T2DM in adults (18
years) with IGT, as defined by a 2-hour plasma glucose
concentration of 140–199 mg/dl during a single OGTT
[29].
In addition, all IGT subjects must have a fasting plasma
glucose of 95–125 mg/dl and at least one of the following:
(i) one or more components of the insulin resistance syn-
drome (low HDL cholesterol [<40 mg/dl in females; <35
mg/dl in males], fasting plasma triglyceride  150 mg/dl,
sitting blood pressure > 135/85 mmHg or on active ther-
apy for hypertension, BMI  25 kg/m2 [BMI  22 kg/m2 for
Asian Americans], waist circumference > 102 cm in men
and > 88 cm in women [>90 cm in Asian American men
and > 80 cm in Asian American women]), (ii) family his-
tory of type 2 diabetes mellitus (1 first degree relatives);
(iii) history of gestational diabetes mellitus; (iv) poly-
cystic ovarian syndrome; (v) minority ethnic background
(Mexican American, African American, Asian, Pacific
Islander, Native American). The inclusion criteria
included: (i) men and women  18 years of age, (ii) all
ethnic groups, (iii) IGT with FPG = 95–125 mg/dl plus at
least one high risk characteristic; IGT is defined as a 2-
hour plasma glucose = 140–199 mg/dl during a single 75BMC Endocrine Disorders 2009, 9:17 http://www.biomedcentral.com/1472-6823/9/17
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gram OGTT; (iv) BMI  25 kg/m2 (no upper limit) (BMI >
22 for Asian Americans). Exclusion criteria are presented
in the Table 1.
During the course of recruitment, the investigators agreed
to modify the glycemic inclusion criteria to allow enroll-
ment of persons with fasting glucose of 90–125 mg/dl as
Table 1: Inclusion/Exclusion Criteria.
• 1. Inclusion Criteria
• Men and women
• All ethnic groups
•  18 years of age
• IGT with a FPG = 95–125 mg/dl plus at least one additional high risk
• characteristic (see text). IGT is defined as a two hour plasma glucose
• concentration = 140–199 mg/dl during a single 75 gram OGTT.
• BMI  25 kg/m2 (no upper limit) (BMI > 22 kg/m2 for Asian Americans)
1. Exclusion Criteria
• Subjects with diabetes mellitus: FPG  126 mg/dl or 2-hour plasma glucose  200 mg/dl during OGTT.
• Subjects previously treated with a thiazolidinedione (ever) or metformin (within one year prior to randomization)
• Subjects previously treated with a sulfonylurea, a meglitinide, an alpha glucosidase inhibitor for more than one week within the last year, or 
within the 3 months prior to randomization
• Subjects previously treated with insulin (other than during pregnancy) for more than one week within the last year or within the 3 months 
prior randomization.
• Medical conditions likely to limit life span and/or increase risk of intervention
- Cardiovascular disease
- Hospitalization for treatment of heart disease or stroke in past 6 months
- New York Heart Association Functional Class > 2
- Left bundle branch block or third degree AV block
- Aortic stenosis
- Systolic blood pressure > 180 mmHg or diastolic blood pressure > 105 mmHg; subjects can be re-screened after treatment of their 
hypertension
- Renal disease (creatine  1.6 mg/dl for men or  1.5 mg/dl for women, or urine protein  2+)
- Anemia (hematocrit < 33% in men and < 30% in women); if the hematocrit increases above these levels at a later date, they can be included 
in the study
• Hepatitis, based on history and/or serum ALT greater than 2.5 times the upper limit of normal
- Other gastrointestinal disease (pancreatitis, inflammatory bowel disease)
- Recent or significant abdominal surgery
- Pulmonary disease with dependence on oxygen or daily use of bronchodilators
- Chronic infection (e.g., HIV, active tuberculosis)
• Conditions or behaviors likely to affect conduct of the trial
- Unwilling to accept treatment assignment by randomization
- Participation in another intervention research project that might interfere with completion of the study
- Weight loss of > 10% in past 6 months for any reason except postpartum weight loss
- Currently pregnant or within 3 months postpartum
- Currently nursing or within 6 weeks of having completed nursing
- Pregnancy anticipated during the course of the trial
- Unwilling to undergo pregnancy testing or report possible pregnancy promptly
- Unwilling to take precautions to avoid pregnancy if potentially fertile
• Major psychiatric disorders
• Excessive alcohol intake, either acute or chronic
• Medications and medical conditions likely to confound the assessment for diabetes, including:
Thiazide diuretics at a dose greater than 25 mg/day
Non-cardioselective beta-blockers 
(individuals receiving treatment with a statin or fenofibrate will not be excluded as long as the dose has been stable for 3 months prior to 
randomization)
Glucocorticoids, systemic
Prescription weight-loss or weight-gain medications
• Thyroid disease, suboptimally treated as indicated by abnormal serum thyroid-stimulating hormone
• Other endocrine disorders (e.g. Cushing's syndrome, acromegaly)
• Fasting plasma triglyceride > 400 mg/dl, despite treatment
• Individuals with a history of bladder cancer
• Individuals with hematuria at screening. However, subjects with hematuria may be randomized if the cause of the hematuria is found, treated, 
and thought unlikely to recur.BMC Endocrine Disorders 2009, 9:17 http://www.biomedcentral.com/1472-6823/9/17
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long as the 2-hour plasma glucose concentration was
170–199 mg/dl, in recognition of the high risk of diabetes
in such persons.
Eight centers took part in the study and the protocol was
approved by the individual IRB of the 8 participating cent-
ers. After ascertaining eligibility and collection of baseline
measures as described below, subjects were randomized
by center and gender using block randomization to ensure
equal distribution. Prior to randomization all subjects
met with a dietician and received 30 minutes of instruc-
tion consistent with the goals of the Diabetes Prevention
Program [16]. These goals emphasized reduced total
caloric intake, decreased fat intake, and walking 30 min-
utes per day for 4–5 days per week. Goals were reinforced
on all follow up visits.
Potentially eligible IGT subjects (n = 1850) were identi-
fied according to recruitment procedures most suited to
each of the 8 participating centers and their written, vol-
untary informed consent was obtained. Subjects then
received a 75 gram oral glucose tolerance test (OGTT)
with samples drawn at -30, -15, 0, and every 15 minutes
thereafter for 2 hours for determination of plasma glu-
cose, insulin, C-peptide, and free fatty acid concentra-
tions. The OGTT was performed at 0800 h following an
overnight fast (after 2000 h). Samples for determination
of plasma glucose concentration were sent to the Central
Laboratory (Texas Diabetes Institute, San Antonio, TX)
and sites were notified about subject eligibility (FPG  95
mg/dl and 2-h PG = 140–199 mg/dl) within 48 hours.
Subjects meeting these criteria returned for a medical his-
tory, physical examination, screening blood tests (chemis-
tries and complete blood cell count), urinalysis, and
electrocardiogram. During this visit or on a subsequent
visit prior to randomization, a fasting blood sample was
obtained for the measurement of HbA1c, and lipid profile,
and plasma and serum were collected for later measure-
ment of novel risk factors. The first voided morning urine
specimen was collected for determination of microalbu-
min to creatinine ratio and a 24-hour urine was collected
for determination of 8-epi-prostaglandin F2 (also termed
15-F2t-IsoP), a measure of oxidative stress [30]. Systolic
and diastolic blood pressures were measured with an
automated Dinamap Pro 100 instrument (GE Medical
Systems, Milwaukee, WI) following 5 minutes in the
reclining position and after 5 minutes in the upright posi-
tion. Ankle-arm blood pressure was measured as
described by Papamichael et al [31].
Body composition was assessed by measurement of body
weight (to the nearest 0.1 kg) on a digital scale (Health-O-
Meter, Bridgeview, IL) and height (to the nearest 0.1 cm).
Waist circumference was measured using the Gulick II
Tape Measure, model #67010 (Gays Mills, WI) at the mid-
point between the highest point at the iliac crest and the
lowest part of the costal margin in the midaxillary line.
Waist circumference was measured in the morning in the
erect position after voiding and following an overnight
fast. Percent body fat and lean body mass were deter-
mined by DEXA using the 4500A Hologic (Bedford, MA)
in 4 of the 8 centers. For quality assurance, a Spine Phan-
tom (Hologic) was scanned every morning and a Step
Phantom (Hologic) was scanned every week. Standardiza-
tion and cross-validation of the DEXA measurement
between the 4 participating centers was achieved by per-
forming 5 consecutive (once daily) measurements using
the same Whole Body Phantom (Hologic) which circu-
lated between all sites. Whole Body Phantom measure-
ments were performed at all sites yearly, for 4 consecutive
years. The percent body fat and lean body mass coeffi-
cients of variation within a given center were 0.8–1.5%
and 0.7–1.5% (depending on the site), respectively. The
percent body fat and lean body mass coefficients of varia-
tion between centers were 3.7% and 6.0%, respectively.
The percent body fat and lean body mass coefficients of
variation between the yearly scans were 0.6% and 0.9%,
respectively.
Within 3–10 days after the OGTT, subjects at 4 centers
were asked to return for a FSIVGTT [32], which was per-
formed at 0800 h following an overnight fast (after 2000
h). A catheter was inserted into an antecubital vein and 3
baseline arterialized blood samples (heated box to 70°C)
were obtained. At time zero glucose (300 mg/kg) was
given as a smooth intravenous bolus over one minute.
Insulin (0.03 units/kg) was given as an intravenous bolus
20 minutes after the start of the glucose injection. Over
the 240 minutes following glucose ingestion, 22 blood
samples were drawn at
2,3,4,5,6,8,10,14,19,22,24,27,30,40,50,70,90,
120,150,180,210, and 240 minutes for determination of
plasma glucose and insulin concentrations.
At 8 AM on a separate day subjects from seven centers had
a measurement of carotid intimal media thickness (IMT)
using B-mode ultrasound (Logiq, GE Medical Systems,
Milwaukee, WI) [33]. A standardized protocol was fol-
lowed by all centers to assure quality control. Prior to ini-
tiation of the study, all ultrasound technologists received
training at the coordinating center, directed by Dr.
Howard Hodis at the University of Southern California, to
ensure uniformity of measurement amongst centers.
Acquisition of an image of the far wall of the common
carotid was obtained and carotid IMT scans were sent to
the coordinating center, where they were read blindly by
two readers, as previously described [33]. In a subset of
subjects at 7 of the 8 centers a second measurement was
performed within 2 weeks of the initial scan to determine
reproducibility and technologist performance. The coeffi-BMC Endocrine Disorders 2009, 9:17 http://www.biomedcentral.com/1472-6823/9/17
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cient of variation of these two measurements was 0.72%
(range = 0.14–0.90). Carotid IMT measurements also
were performed at mid study and at study end (or at time
of diagnosis of diabetes) to examine the rate of change in
carotid IMT.
Recruitment and Following Visits
The first IGT subject was recruited in January of 2004 and
enrollment was completed (n = 602) on February 13,
2006. All subjects were followed until they dropped out,
reached the primary endpoint of diabetes, or reached the
end of the blinded phase of the study 2 years from the
time of recruitment of the last subject, at which time (Feb-
ruary of 2008) all baseline measurements/procedures
were repeated.
Following completion of the baseline studies, IGT sub-
jects were randomized to receive pioglitazone, 30 mg/day,
or placebo and returned 1 month later. If no adverse
events were present, the dose of blinded pioglitazone
(and placebo) was increased to 45 mg/day (maximum
dose) and participants returned for follow-up visits at
2,4,6,8,10, and 12 months during the first year and every
3 months subsequently. On each visit a brief physical
exam was performed, including measurement of weight,
blood pressure, and pulse and the presence or absence of
edema was recorded and graded at each visit, as was infor-
mation for subjective assessment of medication side
effects (excessive weight gain, edema, other). An interim
medical history with a detailed cardiovascular question-
naire was obtained. Blood for determination of fasting
plasma glucose concentration AST and ALT, a urine preg-
nancy test, and measurement of waist circumference were
obtained on each follow up visit. Serum chemistries, CBC,
and urine dipstick for hematuria was performed on each
6 month visit after randomization. HbA1c was measured
every 12 months and the OGTT was repeated every 12
months. Blood for measurement of C-reactive protein,
adipocytkines, markers of inflammation and other
atherosclerotic cardiovascular risk factors was obtained on
the final visit while on active treatment, i.e. 2 years after
the last subject was enrolled, or at the time of diagnosis of
diabetes. An EKG, DEXA, urine for microalbumin/creati-
nine ratio and 15-F2t-IsoP also were obtained on this final
visit. Carotid IMT was measured 15–18 months after ran-
domization and again at the final visit while on active
treatment. The FSIVGTT was repeated on this final visit at
centers participating in the FSIVGTT substudy.
Conversion of IGT to Diabetes
Conversion of IGT to diabetes was made by ADA criteria
[29]: (i) FPG  126 mg/dl or (ii) 2-h PG during OGTT 
200 mg/dl. In either case, the diagnosis of diabetes was
confirmed by an OGTT, whether the initial diagnosis was
made by a FPG  126 mg/dl (i.e., on a 2–3 month follow
up visit or on an annual follow up visit) or with a 2-h PG
 200 mg/dl during the annual OGTT. If the repeat meas-
urement confirmed the diagnosis of diabetes, the primary
endpoint was met and a FSIVGTT/carotid IMT measure-
ment/final visit blood draws were obtained. Any IGT sub-
ject who developed type 2 diabetes (pioglitazone-treated
or placebo groups) was started on open label pioglitazone
(30 mg/day and titrated to 45 mg/day [maximum dose]
after one month), but the randomization code was not
broken. These converters continued with all scheduled
follow up visits/procedures until the study was completed
(February of 2008). If the HbA1c or FPG increased to
8.0% or 180 mg/dl, respectively, while an open label
pioglitazone, the OGTT/FSIVGTT/close out visit were per-
formed and appropriate additional antidiabetic therapy
started.
A Data Safety Monitoring Board received a copy of all
adverse events, as well as detailed information about body
weight, edema, AST/ALT, and other medication side
effects monthly. The DSMB had a teleconference every 6
months to review all safety data. All cardiovascular events
and EKG documented myocardial infarctions will be
reviewed by an adjudication committee.
Measurements
All analytical measurements were performed in a central
laboratory at the Texas Diabetes Institute (San Antonio,
TX). Plasma glucose concentration was measured by the
glucose oxidase reaction (Glucose Oxidase Analyzer,
Beckman Instruments, Fullerton, CA). Plasma insulin was
measured by radioimmunoassay (Diagnostic Products,
Los Angeles, CA). The interassay and intra-assay CVs for
the insulin assay are 7.1% and 5.1%, respectively. Plasma
C-peptide was measured by radioimmunoassay (Diagnos-
tic Systems, Webster, TX). The interassay and intra-assay
CVs for the C-peptide assay are 2.4% and 4.3%, respec-
tively. HbA1c was measured by an ion-exchange HPLC
instrument (Bayer DCA 2000, Leverkusen, Germany).
Total plasma cholesterol and triglycerides were measured
using the CHOD-DAOS method (WAKO, Richmond, VA)
and an enzymatic assay (Stanbio Lab, Boerne, TX). HDL
cholesterol was measured after precipitation of apolipo-
protein B-containing lipoproteins with dextran sulfate-
Mg++, using the CHOD-DAOS method (WAKO, Rich-
mond, VA). LDL cholesterol was calculated by the Friede-
wald equation.
Calculations
Incremental area under the curve (AUC) for plasma glu-
cose and insulin concentrations during the OGTT was cal-
culated according to the trapezoidal rule. The
insulinogenic index was calculated as I(AUC)/G(AUC)
from 0–30 and 0–120 minutes [21,22]. The insulin secre-
tory rate during the OGTT was calculated by deconvolu-BMC Endocrine Disorders 2009, 9:17 http://www.biomedcentral.com/1472-6823/9/17
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tion of the plasma C-peptide curve [34] and expressed as
ISR/G [21,22,35].
During the FSIVGTT, first phase insulin secretion was cal-
culated as the increment in plasma insulin concentration
(AUC) above baseline from 0–10 minutes and as the peak
increment in plasma insulin concentration (minus base-
line) during the 0–10 minute time period. Indices of insu-
lin sensitivity (SI) and glucose effectiveness (SG) were
determined by minimal model analysis of insulin and
glucose concentrations during the FSIVGTT as previously
described [32].
The insulin secretion/insulin resistance or disposition
index during the OGTT was calculated as I/G × Matsuda
index and as I/G × SI [32,36]. The hepatic insulin resist-
ance index was calculated as the FPI × FPG (equivalent to
inverse of HOMA) [37]. The basal adipocyte insulin resist-
ance index was calculated as the fasting plasma insulin
(FPI) × fasting plasma FFA concentrations [38].
Statistical Analysis and Sample Size
General Statistical Plan: Analysis of primary and second-
ary endpoints will utilize the intent-to-treat approach
[39]. All participants will be included in their randomly
assigned pioglitazone or placebo treatment groups. All
statistical tests will be two-sided and require alpha = 0.05
to be considered significant.
Primary and Secondary Endpoints
The primary endpoint is the development of diabetes mel-
litus according to ADA criteria [29]. Accordingly, the prin-
cipal analysis will be a life-table analysis of the time from
randomization to the confirmed development of diabe-
tes. Separate life-table estimated cumulative incidence
curves will be calculated for the pioglitazone-treated and
placebo-treated groups, which will be compared using a
logrank test [38,40]. Subjects who are lost to follow up or
who prematurely decide to drop out of the study will be
categorized according to data obtained up to their last fol-
low-up visit.
Secondary outcomes (i.e., cardiovascular events and mor-
tality) will be compared using the same life-table analysis
described above for the primary endpoints.
Repeated measures data (i.e., FPG, 2-hour plasma glucose
during OGTT, HbA1c, measures of insulin secretion and
insulin sensitivity, plasma lipids and other cardiovascular
risk factors, blood pressure, carotid initmal media thick-
ness, body weight and BMI, measures of fat mass and fat
topography) will be compared between the pioglitazone-
treated and placebo-treated groups using longitudinal
data methods: (i) point prevalence of a discrete character-
istic (i.e., normal or impaired glucose tolerance) at
repeated visits over time [40] and (ii) multivariate rank
analysis of quantitative (i.e., FPG, 2-hour plasma glucose,
HbA1c, plasma lipids, plasma cardiovascular risk factors,
etc) variables over repeated visits [40]. Differences in
slopes over time (i.e., rate of change in FPG, 2-hour
plasma glucose, HbA1c, plasma lipids, etc) between piogl-
itazone-treated and placebo-treated groups will be com-
pared by the parametric linear random effects model [41].
Sample Size
The conversion rate of IGT to diabetes varies considerably
based upon ethnicity and a number of other risk factors.
The DPP [42] cited 21 studies with conversion rates (per-
cent per year) ranging from 2.3% to 11%. In addition,
they evaluated data sets from six population based
cohorts [43]. The conversion rate from IGT to diabetes in
these six studies was 5.8 per 100 person-years for follow-
up and rose to 8.2 per 100 person-years for individuals
with a fasting plasma glucose concentration > 100 mg/dl.
In certain ethnic groups, (i.e., Latinos with a history of
GDM), much higher conversion rates of IGT to diabetes
(14.3% per year) have been reported [18,44]. The DPP
[15] demonstrated a conversion rate of IGT to diabetes of
approximately 11% per year. In the group of IGT subjects
treated with diet/exercise and metformin, the conversion
rates were decreased by 58% and 31%, respectively. In the
TRIPOD study [18], GDM women treated with placebo
converted to diabetes at a rate of 12.1% per year and this
rate was decreased to 5.4% in the troglitazone-treated
group. Based upon this information (see assumptions
below), it can be calculated that approximately 600 sub-
jects with IGT will be required to achieve 90% statistical
power that pioglitazone decreases the conversion rate of
IGT to type 2 diabetes by 50%. This power calculation
assumes that randomized individuals drop out prior to
the confirmed diagnosis of diabetes with an exponential
hazard rate of 0.10 (or less) per year.
The following assumptions were used to calculate the
sample size:
(i) The primary endpoint is the development of diabe-
tes,
(ii) Participants are randomized over a 21 month
period and followed for a total of 3.75 years, starting
from the time that the first IGT subject is recruited,
(iii) Type I error rate (alpha) is 0.05,
(iv) The desired power is 90%,
(v) The development of diabetes in the placebo-
treated group is 11% per year,BMC Endocrine Disorders 2009, 9:17 http://www.biomedcentral.com/1472-6823/9/17
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(vi) The hazard rate for the development of diabetes in
the pioglitazone-treated group is reduced by 50%.
(vii) The drop out rate is 10% per year
During the course of recruitment, it became clear that the
recruitment goal would not be reached in the planned 21
month period allotted for recruitment. To preserve study
power, the recruitment period was lengthened 3 months
to a total of 24 months to allow recruitment of the tar-
geted number of participants with a commensurate
increase in the total study duration for a follow up time of
4 years, starting from the time that the first IGT subject
was recruited.
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